Journey Medical Corp
DERM
查看详细走势图
8.010USD
+0.140+1.78%
收盘 12/22, 16:00（美东）报价延迟15分钟
211.24M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+1.78%
5天
+4.03%
1月
+7.37%
6月
+23.04%
今年开始到现在
+104.86%
1年
+71.15%
查看详细走势图
TradingKey Journey Medical Corp股票评分
单位: USD 更新时间: 2025-12-19操作建议
Journey Medical Corp当前公司基本面数据相对健康，增长潜力很大。当前估值合理，在药品行业排名67/158位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价13.50。中期看，股价处于上升通道。近一个月，市场表现较强，技术面和基本面综合得分较高，较强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Journey Medical Corp评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
4
位分析师
买入
评级
13.500
目标均价
+64.63%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Journey Medical Corp亮点
亮点风险
Journey Medical Corporation is a commercial-stage pharmaceutical company. The Company is focused on selling and marketing of the United States Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved FDA for sale in the United States, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox, and Luxamend. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne. Luxamend is a water-based emulsion formulated to provide moist healing environment.
业绩增长期
公司处于发展阶段，最新年度总收入56.13M美元
估值低估
公司最新PE估值-22.81，处于3年历史低位
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓，最新持仓市值247.90K
活跃度增加
近期活跃度增加，过去20天平均换手率0.31
Journey Medical Corp新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Journey Medical Corp简介
Journey Medical Corporation is a commercial-stage pharmaceutical company. The Company is focused on selling and marketing of the United States Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved FDA for sale in the United States, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox, and Luxamend. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne. Luxamend is a water-based emulsion formulated to provide moist healing environment.
公司代码DERM
公司Journey Medical Corp
CEOMaraoui (Claude)
网址https://journeymedicalcorp.com/
常见问题
Journey Medical Corp(DERM)的当前股价是多少？
Journey Medical Corp(DERM)的当前股价是 8.010。
Journey Medical Corp的股票代码是什么？
Journey Medical Corp的股票代码是DERM。
Journey Medical Corp股票的52周最高点是多少？
Journey Medical Corp股票的52周最高点是9.400。
Journey Medical Corp股票的52周最低点是多少？
Journey Medical Corp股票的52周最低点是3.535。
Journey Medical Corp的市值是多少？
Journey Medical Corp的市值是211.24M。
Journey Medical Corp的净利润是多少？
Journey Medical Corp的净利润为-14.67M。
现在Journey Medical Corp(DERM)的股票是买入、持有还是卖出？
根据分析师评级，Journey Medical Corp(DERM)的总体评级为买入，目标价格为13.500。
Journey Medical Corp(DERM)股票的每股收益（EPS TTM）是多少
Journey Medical Corp(DERM)股票的每股收益（EPS TTM）是-0.345。
相关品种
